Immatics (NASDAQ:IMTX - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $3.88 and last traded at $4.24, with a volume of 402269 shares changing hands. The stock had previously closed at $4.00.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $16.67.
View Our Latest Analysis on Immatics
Immatics Trading Up 5.9 %
The stock has a market cap of $442.21 million, a PE ratio of -5.61 and a beta of 0.85. The company's 50 day moving average is $4.81 and its 200-day moving average is $7.13.
Immatics (NASDAQ:IMTX - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.51. The business had revenue of $15.67 million for the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. As a group, analysts forecast that Immatics will post -0.72 EPS for the current year.
Institutional Trading of Immatics
A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after acquiring an additional 2,231 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in shares of Immatics by 34.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after purchasing an additional 2,479 shares during the last quarter. Guggenheim Capital LLC acquired a new position in Immatics in the fourth quarter worth about $101,000. Forefront Analytics LLC increased its holdings in Immatics by 42.3% in the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock valued at $113,000 after buying an additional 4,731 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in Immatics during the fourth quarter valued at approximately $130,000. Institutional investors and hedge funds own 64.41% of the company's stock.
About Immatics
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Further Reading
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
